(Q48370561)

11 February 2018

title

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. (English)

1 reference

11 February 2018

0 references

1 reference

7

Frederik Barkhof

1 reference

11 February 2018

10

Joep Killestein

1 reference

11 February 2018

author name string

Anke Vennegoor

1

1 reference

11 February 2018

Theo Rispens

2

1 reference

11 February 2018

Eva Mm Strijbis

3

1 reference

11 February 2018

Alexandra Seewann

4

1 reference

11 February 2018

Bernard Mj Uitdehaag

5

1 reference

11 February 2018

Lisanne J Balk

6

1 reference

11 February 2018

Chris H Polman

8

1 reference

11 February 2018

Gertjan Wolbink

9

1 reference

11 February 2018

publication date

19 September 2012

1 reference

11 February 2018

Multiple Sclerosis Journal

published in

1 reference

11 February 2018

volume

19

1 reference

11 February 2018

issue

5

1 reference

11 February 2018

page(s)

593-600

1 reference

11 February 2018

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512460604

21 January 2018

Identifiers

DOI

10.1177/1352458512460604

1 reference

11 February 2018

1 reference

11 February 2018